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9Introduction
Cardiomyopathies constitute a group of heart muscle diseases
of varied etiology that are treatablewithmedical therapies, but
cardiac function generally declines despite therapy. Most
cardiomyopathies at the stage of heart failure exhibit cardio-
myocyte loss. Adult mammals do not sufficiently regenerate
cardiomyocytes to compensate for lost cardiomyocytes. Cardiac
transplantation is the only proven method to replace lost
cardiomyocytes. In light of insufficient numbers of donor
organs, stimulating myocardial regeneration offers a potential
strategy for treating heart failure.
In contrast to adult mammals, amphibians, reptiles, and
zebrafish regenerate cardiomyocytes after myocardial injury
(Jopling et al., 2010; Oberpriller and Oberpriller, 1974). The
research community has directed attention to two principal
strategies to regenerate myocardium: Use of stem and
progenitor cells to repair damaged myocardium and enhance-
ment of endogenous regenerative mechanisms (Garbern and
Lee, 2013). This review focuses on endogenous regeneration
mechanisms by cardiomyocyte proliferation.Historical and current perspectives in
cardiac regeneration
Anecdotal reports over the past 100 years have shown mitoses
of cardiomyocyte nuclei; however, evidence for cardiomyo-
cyte division remained elusive. The first systematic and
quantitative examinations of the cellular mechanisms of
human heart growth were published in the 1950s (Linzbach,
1950; Linzbach, 1960). One study examined the increase of
cardiomyocyte cross-sectional area in the left ventricular
papillary muscle in humans and concluded that cardiomyocyte
enlargement could fully account for physiologic myocardial
growth between birth and adulthood (Linzbach, 1950, 1960).
Because examining orthogonally sectioned papillarymuscles is
associated with biases, the validity of extrapolating these
results to the entire heart is limited. Still, historically, the
mammalian heart has been viewed as a post-mitotic organ in
which the primary parenchymal cells, cardiomyocytes, do not
increase in number after birth (Zak, 1973; Linzbach, 1950).
Additional classical studies of cardiomyocyte proliferation
used microscopy to visualize mitotic figures. However, these
approaches probably did not have the precision necessary for
definitive visualization of cardiomyocyte cytokinesis nor the
throughput for quantifying rare events. Although not conclu-
sive, these studies led to two paradigms: First, unlike skeletal
muscle, the adult heart does not have progenitors supportingthe generation of new cardiomyocytes. The second paradigm
argued that there is a single cellular mechanism of post-natal
developmental and pathological heart growth: cardiomyocyte
enlargement (Rumyantsev and Carlson, 1991; Borisov and
Claycomb, 1995). In the latter-20th century, technical ad-
vances, including use of confocal microscopy to visualize cell
cycle events, automated analyses of large cell populations, and
genetic and metabolic labeling for cellular fate mapping, have
provided new data. This has advanced a new cellular paradigm,
which includes adult cardiomyocyte renewal, while incorporat-
ing the significant role that cardiomyocyte enlargement plays in
physiologic and pathologic heart growth.
The recognition of endogenous cardiomyocytes as a source
for new cardiomyocytes raises the possibility of stimulating this
process formyocardial repair. By understanding themechanisms
limiting the regenerative response of mammalian myocardium,
therapeutic strategies could be developed. To realize this
therapeutic potential, the scientific community needs to
address questions involving the precise cellular source for new
cardiomyocytes, the regulating signaling pathways, the under-
lying cellular mechanisms, and the genesis rates and dynamics.Mechanisms of cardiomyocyte regeneration
pose challenges for investigation
Cardiomyocyte generation in the adult mammalian heart is a
slow process compared with the blood, skin, and the digestive
system, which makes it difficult to characterize turnover
dynamics. In situ time lapse imaging of the beating mammalian
heart at cellular resolution is technically challenging
(Hashimoto et al., 2014; Hesse et al., 2012). Myocardial biopsies
from patients provide only a small amount of tissue for analysis.
The cellular heterogeneity and close spatial packing of cells in
the myocardium can obscure the identification of cardiomyo-
cyte nuclei from neighboring non-cardiomyocytes (Soonpaa and
Field, 1997; Soonpaa et al., 2012). Perhaps themost challenging
aspect is that cardiomyocytes exhibit non-proliferative cell
cycles that increase the DNA content without cell division.
Despite these intrinsic biological features that complicate
studying regeneration, several new methods have enabled the
advance of our understanding of cardiomyocyte proliferation.Classical and new methods have advanced
cardiac regeneration research
Labeled thymidine and thymidine analogs are stably incorpo-
rated into the genome during DNA synthesis and can be used to
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limited by potential radioactive toxicity due to long-term
administration and by lower spatial resolution of visualization
by autoradiography, compared with confocal microscopy
(Soonpaa and Field, 1997). The early manual analysis of
autoradiographs of tritiated thymidine in isolated
cardiomyocytes fits with recent studies almost 2 decades
later (Soonpaa and Field, 1997; Li et al., 1996; Senyo et al.,
2013; Soonpaa et al., 1996). Thymidine analogs such as
bromo-deoxyuridine (BrdU) have also been administered for
up to several weeks for detecting cardiomyocyte cell cycle
activity. Though high concentrations of BrdU can affect cell
proliferation and differentiation, adverse effects were not
reported with long-term labeling (Wilson et al., 2008;
Malliaras et al., 2013). Similar to Soonpaa et al. with a tritium
label, Li et al., using a single BrdU injection, observed
progressive loss of cardiomyocyte-DNA synthesis in rats within
ten days of birth (Li et al., 1996; Soonpaa et al., 1996).
However, it should be noted that using Ki67 as amarker,Walsh
et al. detected cell cycle activity in cardiomyocyte nuclei in
mice up to 21 days of age (Walsh et al., 2010). Naqvi et al.
detected BrdU uptake and markers of mitosis and cytokinesis
in cardiomyocytes in 13–15 day-old mice (Naqvi et al., 2014).
In the adult heart, Soonpaa et al. examined mice 2 h after
administration of tritiated thymidine (3 injections, 12-hour
intervals) and determined a 0.0005% labeling frequency of
cardiomyocytes expressing a transgenic marker from the
α-MHC-promoter (Soonpaa and Field, 1997). More recently,
the use of long term BrdU labeling demonstrated a low basal
activity of cardiomyocyte proliferation though an order higher
than previously reported (Li et al., 1996; Malliaras et al., 2013).
Antibodies raised against markers of the cell cycle can be
used for visualization bymicroscopy (e.g. Ki67 for G1, S, G2 and
M-phase, phospho-histone3 for M-phase, Aurora B kinase for
cytokinesis) (Senyo et al., 2013; Malliaras et al., 2013; Ellison
et al., 2013; Mollova et al., 2013). Antibody-based detection
has the advantage of broad applicability, but is potentially
susceptible to false-positives and -negatives. These issues can
be addressed with appropriate negative controls. It should be
noted that Ki-67 is present in G1-, S-, G2-, and M-phase of the
cell cycle. Thus, for mechanistic studies, Ki-67 assays should be
combined with other, more specific cell cycle markers.
Automated systems provide an unbiased approach for
sampling large numbers of cardiomyocytes, but so far, they
require dispersed cells. Flow cytometry (FACS) and laser
scanning cytometry (LSC) offer high throughput methods
to detect and quantify antibody labeling of isolated
cardiomyocytes or nuclei (Malliaras et al., 2013; Walsh et
al., 2010; Mollova et al., 2013). Recently, we examined
cardiomyocyte cycling in humans using the M-phase marker
phospho-histone3 and used LSC for read-out. This demon-
strated a decrease in cardiomyocyte proliferation between
birth and 20 years of life in humans (Mollova et al., 2013).
We compared the LSC results with visual quantification of
H3P-positive cardiomyocyte nuclei on stained cryosections,
which reproduced the pattern of decreasing H3P-activity
between birth and 20 years (Mollova et al., 2013). LSC in
humans and FACS in mice showed agreement in that the
frequency of cardiomyocyte cell cycle activity decreases
after birth (Walsh et al., 2010; Mollova et al., 2013).
Carbon-14 birth dating is an approach devised by the Frisen
group to monitor cellular turnover in tissue (Bergmann et al.,2009). This strategy makes use of the transient increase of
carbon-14 (14C) in the biosphere due to a period of above ground
nuclear testing that ended in the 1960s. The carbon-14 was
taken up by humans through the diet and incorporated into the
genomic DNA, which can be used as a time-stamp to calculate
the mean birth date of a stable cell population (Bergmann et
al., 2009). The carbon-14 content in cardiomyocyte nuclear
DNA is quantified using accelerator mass spectrometry (AMS,
which has a lower detection limit of 10−21 moles). Themean age
of cardiomyocytes is then compared with the age of the source
individual. This indicated generation of new cardiomyocytes at
a rate of ~1% after 25 years of age. The fidelity of this approach
depends on the quality of cardiomyocyte nuclei isolated from
post-mortem myocardium. AMS provides a tissue-average,
which poses a challenge since in cardiomyocytes, S-phase can
be connected with cell division and differentiation. Hence, the
analysis relied on additional assumptions that had to be made
for mathematical modeling of the data (Bergmann et al., 2009),
including assumptions about potential changes of the number of
cardiomyocytes after birth, rates of cardiomyocyte cell death,
and the extent of non-proliferative cell cycles (multinucleation
and ploidy) with age (Elser and Margulies, 2012).
Fate mapping with genetic tags has been used to label
distinct cell populations to determine the source of new cells
with time or intervention. Multiple groups have used the α-MHC
promoter driven Cre model crossed with reporter lines to assay
the role of progenitor cells in the generation of new
cardiomyocytes after injury (Senyo et al., 2013; Malliaras et
al., 2013; Ellison et al., 2013). After tamoxifen induction, a
majority of differentiated cardiomyocytes is labeled with a
reporter such as green fluorescent protein (GFP) or LacZ (Senyo
et al., 2013; Porrello et al., 2012). Using this technique, we
have demonstrated that during normal aging in mice, the
percent of preexisting cardiomyocytes, indicated by the
percentage of GFP-positive cardiomyocytes, remains un-
changed (Hsieh et al., 2007). Influx of cardiomyocytes
generated from undifferentiated progenitor cells should result
in a decrease of the percentage of GFP-labeled (preexisting)
cardiomyocytes. This “dilution” was the case after experimen-
tal myocardial infarction, leading to the conclusion that
myocardial injury induced an influx of progenitor cell-derived
cardiomyocytes (Hsieh et al., 2007). However, multiple other
studies showed very little or no contribution of progenitor cells
to generating cardiomyocytes in adult mammals (Senyo et al.,
2013; Malliaras et al., 2013; Ellison et al., 2013; Porrello et al.,
2012; Loffredo et al., 2011). Considering one specific progenitor
type, Ellison et al. reported a 0.15% generation rate for c-kit
progenitor-derived cardiomyocytes in a 4-week period of
normal aging (Ellison et al., 2013). This contrasts with results
from using a knock-in of an inducible Cre into the c-kit gene
locus (van Berlo et al., 2014). This more direct approach
demonstrated that c-kit positive cells do not generate
cardiomyocytes in mice after birth to a significant degree (van
Berlo et al., 2014). In this context, it is important to note that
c-kit positive cells isolated from neonatal mice can generate
cardiomyocytes (Zaruba et al., 2010). Systematic molecular
characterization of myocardial c-kit cells and comparison with
the cardiomyocyte lineage should help resolve this controversy.
Potential explanations of our discrepant results with the
genetic α-MHC-MerCreMer/ZEG fate mapping techniques in-
clude cardiomyocyte toxicity due to high expression levels of
Cre (Lexow et al., 2013; Bersell et al., 2013). However, we did
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5-hydroxy-tamoxifen (Loffredo et al., 2011; Lexow et al., 2013;
Bersell et al., 2013; Koitabashi et al., 2009). A concern of
genetic tags expressed under control of cell-specific promoters
is the dependence on the fidelity of transcriptional activity. In
addition, it may be possible that the labeled cell population is
phenotypically heterogenous. This possibility must be consid-
ered when the genetic labeling technique does not label the
entire cell population, as is the case with the α-MHCMerCreMer
mice (Sohal et al., 2001). Other genetic approaches such as
retrospective clonal assays utilize random labeling of precursor
cells and have been used to address lineage in early cardiac
development (Ali et al., 2014; Buckingham and Meilhac, 2011).
This system selectively labels daughter cells of mononucleated
cells in divergent fluorescent tags so that one cell is labeled
with red and the other with green. Using two transgenic models
for a cardiomyocyte specific source and a non-discriminate
source, respectively, Ali et al. demonstrated that very few new
mononucleated cardiomyocytes are generated primarily from
pre-existing cardiomyocytes (Ali et al., 2014). Genetic labeling
remains one of the most powerful approaches to monitor cell
population dynamics, if applied appropriately.
Stable isotopes can be used to mark biological molecules for
monitoring cell cycle activity over long periods. Stable
isotope-labeled biomolecules are integrated into cells without
disrupting biological functions. The safety of stable isotope
labels allows long-term labeling strategies to both characterize
events over extended periods and record rare events. The
read-out utilizes a high-resolution analytical imaging system
called multi-isotope imaging mass spectrometry (MIMS). The
MIMS platform was developed by Dr. Claude Lechene at the
National Resource for Imaging Mass Spectrometry as a
quantitative approach to image biological processes
(Steinhauser and Lechene, 2013). MIMS generates detailed
quantitative images based on the isotope composition of the
sample surface. The spatial resolution of MIMS is similar to
electron microscopy and can be used for analyzing sub-cellular
structures, including chromatin, cytoplasmic proteins, and
organelles. Thymidine marked with nitrogen-15 (15N, the rare
stable isotope of the abundant nitrogen-14) can be introduced
into cell culture media or animals and is incorporated into the
genome to make an in situ record of DNA synthesis. We have
used this approach for quantifying several successive cell
divisions in the intestine (Steinhauser et al., 2012). In Senyo et
al., we employed this approach to study cardiomyocyte
turnover (Senyo et al., 2013).
Cardiomyocyte cell cycle activity decreases
during post-natal development
After birth, most mammalian cardiomyocytes transition from
proliferation to terminal differentiation. The terminally differ-
entiated phenotype is commonly characterized as having no
proliferative potential. Cardiomyocyte DNA-synthesis activity
decreases during the first 1–2 weeks of life in rodents (Li et al.,
1996; Soonpaa et al., 1996). However, flow cytometry analysis
has detected cardiomyocytes positive for the cell cycle marker
Ki-67 in mice up to 2–3 weeks of age (Walsh et al., 2010;
Ikenishi et al., 2012). We have detected cardiomyocytes
positive for the mitosis marker H3P in humans in the first
20 years of adult life, after which the activity was very low(Mollova et al., 2013). Inmice, we administered isotope-labeled
thymidine for 8 weeks to increase our sensitivity of detecting
cardiomyocyte cell cycle activity. By MIMS analysis, we
measured a 56% labeling index of cardiomyocytes with at least
one cell cycle event in mice in the first 2 months of life. Using
the same labeling protocol, adult mice exhibited a significant
decrease of cardiomyocytes with history of cell cycle activity
(0.84% over 2 months; 0.015%/day). Due to the 8 week-long
duration of labeling, we could not determine the specific time
pattern of cell cycle withdrawal during the neonatal period. In
summary, the post-natal period during which cardiomyocyte
cell cycle activity decreases is much longer in humans, as
compared with mice and rats. All three species show extremely
low cardiomyocyte cell cycle activity as adults.
Post-natal cardiomyocyte cell cycle activity may be associ-
ated with proliferation, resulting in a change of the number of
cardiomyocytes. A study using biochemical quantification of
cardiac DNA content reported an increase in cardiomyocyte
number in humans after birth (Adler and Costabel, 1975). Our
direct stereologic quantifications of cardiomyocyte numbers in
humans demonstrated an increase from 1.1 to 3.7 billion
cardiomyocytes from birth to age 20 years (Mollova et al.,
2013). A recent study showed an increase of the number of
cardiomyocytes in pre-adolescent mice by 40% (Naqvi et al.,
2014). Manual counting of isolated cardiomyocytes in rats
showed an increase from 13.6 to 22.9 billion from birth to day 3
(Li et al., 1996). In summary, post-natal cardiomyocyte
proliferation has been documented in mice, rats, and humans.
However, the time period during which this happens varies
widely.
After birth, rodent cardiomyocytes transition from cell
division to incomplete cell cycles, resulting in approximately
80–90% binucleated cardiomyocytes in adult mice and rats.
Humans are borne with approximately 30% of cardiomyocytes
being binucleated, and this proportion does not change
significantly after birth (Mollova et al., 2013). However, in
humans the ploidy of cardiomyocyte nuclei increases between
birth and adulthood (Mollova et al., 2013; Adler and Costabel,
1975).Molecular changes associated with cell cycle
withdrawal have been described, but molecular
mechanisms of terminal differentiation remain
largely uncharacterized
The transition to the terminally differentiated phenotype is
accompanied by down-regulation of cell cycle factors and
up-regulation of cell cycle inhibitors (Soonpaa et al., 1996;
Mollova et al., 2013; Adler and Costabel, 1975; Brooks et al.,
1998; Poolman and Brooks, 1998). Cell cycle activators such as
the Cdk/cyclin complex, Myc, E2F transcription factors were
demonstrated to be repressed. Negative cell cycle regulators
are increased, such as p21, p27, retinoblastoma protein, and
cyclin-dependent kinase inhibitors (Pasumarthi and Field, 2002;
Li et al., 1998; Flink et al., 1998). However, the functional
relevance of these associations has not been fully character-
ized. Decreased cardiomyocyte cell cycle activity was shown to
be associated with the increase of the tissue oxygen tension
upon birth, leading to increased cardiomyocyte DNA damage
(Puente et al., 2014).
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turnover in the mammalian heart is very lowTurnover is the dropout and generation of new cells without a
change of the total number of cells in the organ, i.e. during
homeostasis. The number of cardiomyocytes per heart is
important when considering the rate of cardiomyocyte turnover
and regeneration. Few studies have quantified the number of
cardiomyocytes in human hearts (Hsieh et al., 2007; Lesauskaite
et al., 2004). Using stereology, we quantified the number of
cardiomyocytes in adult humans to be approximately 3.7 billion
(n = 7), corresponding to 5.6 billion cardiomyocyte nuclei
(Mollova et al., 2013). Our results are between the results
from another stereology study that quantified the number of
cardiomyocyte nuclei in adult humans to be 9.5 billion (n = 6
hearts, ref. (Tang et al., 2009)), and a study using biochemical
techniques, which showed 2 billion cardiomyocytes (n = 30, ref.
(Adler and Costabel, 1975)).
Quantification of cardiomyocyte loss is challenging. Apopto-
sis markers are reported to have variable sensitivity. DNA repair
and postmortem enzymatic degradationmay yield false-positive
results with the terminal deoxynucleotidyl transferase (TdT)
dUTP Nick-End Labeling (TUNEL) assay (Lesauskaite et al., 2004;
Saraste and Pulkki, 2000). The irreversible progression of cell
death in cells expressing late stage apoptosis markers has also
been called into question in several organs, including the heart
(Tang et al., 2012). Thus, there is a lack of consensus for the
frequency of cardiomyocyte apoptosis in normal hearts, with
estimates varying by more than an order of magnitude
(Lesauskaite et al., 2004; Saraste and Pulkki, 2000; Wencker et
al., 2003; Chen et al., 2001; Vulapalli et al., 2002).
Cardiomyocyte turnover was quantified with different
techniques. The carbon-14 birth dating strategy showed that
adult humans turn over approximately 0.5% of cardiomyocytes
per year (Bergmann et al., 2009). Our MIMS approach showed a
turnover rate of approximately 1% in adult mice (Senyo et al.,
2013). Several groups found multinucleation and polyploidy to
account for a majority of cell cycle events after the first two
weeks of life in murines (Senyo et al., 2013; Malliaras et al.,
2013; Walsh et al., 2010). Using immunofluorescence micros-
copy, we have not been able to detect cardiomyocytes in
cytokinesis in adult humans (Mollova et al., 2013). Overall,
reported rates of cardiomyocyte turnover in adult mice and
humans are converging at approximately 1% or less per year
(Senyo et al., 2013; Soonpaa et al., 1996; Mollova et al., 2013;
Bergmann et al., 2009).
We have utilized the α-MHC-MerCreMer; Z/EG mice for cell
lineage tracing in concertwith stable isotope-labeled thymidine
to detect cardiomyocytes with a history of cell cycle activity
(Senyo et al., 2013). Approximately 80% of preexisting
cardiomyocytes were genetically labeled with GFP by injection
of 4-hydroxy-tamoxifen. We have labeled with isotope-labeled
thymidine for four to ten weeks at different points after birth.
We used MIMS analysis of histological sections to visualize
isotope-labeled thymidine localization. We identified cardio-
myocyte nuclei by staining for cardiac markers (sarcomeric
actin) and nuclei (DAPI or PAS histological staining). To analyze
multi-nucleated cardiomyocytes, we used fiduciary marks on
sections to retrieve corresponding nuclei on adjacent sections.
Fluorescent in situ hybridization in at least two sections on
either side of the MIMS section was used to determine ploidy.Using this method, we quantified that b1% mononucleated
diploid cardiomyocytes per year in adult mice were generated.
The source of cardiomyocytes generated during turnover
remains an active area of research. Data support a role for
both progenitor differentiation and cardiomyocyte prolifera-
tion. A more expansive discussion of cardiogenic progenitor
potential in the adult heart is described in other articles in this
series of reviews. In short, several classes of progenitor cells
both in development and in the adult myocardium have been
reported to contribute to the generation of cardiomyocytes.
Cardiomyocyte cycling increases after
myocardial injury, but does not lead to
effective regeneration
In adult mice after experimental myocardial infarction, the
border zone shows a 10-fold increase of cardiomyocyte cell
cycle activity. As described above, the α-MHC-MerCreMer
mouse in combination with Cre-reporter lines has the
potential to distinguish progenitor and cardiomyocyte contri-
butions to cardiomyocyte generation (Sohal et al., 2001).
Injection of tamoxifen prior to inducing injury triggers GFP
expression in cardiomyocytes. After injury, an increase of the
GFP-negative percentage is interpreted as generation of
cardiomyocytes derived from a progenitor pool. Using this
system, Malliaras et al. demonstrated a role for proliferative
cardiomyocytes in adult mouse hearts, but a larger role for
progenitor cells (Malliaras et al., 2013).
Combining the Cremodel with stable isotopemapping on the
MIMS platform, we have found that cell cycle activity occurs
primarily in preexisting cardiomyocytes (Senyo et al., 2013).
While this study replicated our previous finding of the dilution of
GFP+ cardiomyocytes, indicative of progenitor differentiation
(Hsieh et al., 2007; Loffredo et al., 2011), we observed cell
cycle activity by stable isotope labeling in preexisting
cardiomyocytes in the injury border (Senyo et al., 2013). This
contrasts with our previous reports that demonstrated gener-
ation of cardiomyocytes from undifferentiated progenitor cells
(Hsieh et al., 2007; Loffredo et al., 2011). These differences
may be due to different long-term viability of GFP− and GFP+
cardiomyocytes, although our evaluation of short-term prolif-
eration and apoptosis rates did not show differences.
Examining the mechanisms of cardiac regeneration when
cardiomyocyte cell cycling and proliferation are active may
provide new insight. Such studies were enabled by emulating
the zebrafish model of excising 10–20% of the ventricular
myocardium (Poss et al., 2002). This was achieved by the
Sadek group in 2011 (Porrello et al., 2011; Heallen et al.,
2013). The apical resection model was reported to increase
cardiomyocytes in M-phase and cytokinesis in neonatal mice
(Porrello et al., 2011). The authors demonstrated scarless
myocardial repair and proliferation of preexisting
cardiomyocytes using a Cre model combined with BrdU
labeling. The aspects of scarless repair and increased
cardiomyocyte cell cycle activity after apical amputation in
neonatal mice have recently been challenged (Andersen et
al., 2014; Sadek et al., 2014). The difference in terms of
scarless repair may be due to our inability to demarcate the
resection level. Given the challenges of apical resection, the
myocardial infarction (MI) approach by ligation of the left
anterior descending coronary artery (LAD) in the neonatal
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Porrello et al., 2013). This model represents a more relevant
model for inducing an injury and offers the advantage of using
a defined landmark for inducing injury. However, the
challenge of this technique is the need for microsurgical skills
for identifying the LAD. Mastering these neonatal mouse
models is required for advancing our understanding of
post-natal cardiomyocyte proliferation in the setting of injury.
There is anecdotal clinical evidence that the human heart has
regenerative potential. For example, an ectopic heart trans-
plant recipient recovered normal function of the original heart,
thus allowing the donor heart to be removed (Tsang et al.,
2009). Examinations of the mechanisms and degree of cardiac
regeneration are technically difficult in humans for ethical
reasons because they require pieces of myocardium for analysis.
Mechanisms of cycling and division of
differentiated cardiomyocytes
The term ‘terminally differentiated cardiomyocyte’ in the
context of cardiac regeneration is meant to describe the
cardiomyocyte phenotype that lacks proliferative capacity,
that is, these cardiomyocytes do not actively cycle nor can
they be stimulated to re-enter the cell cycle. In the adult
mammalian heart, terminally differentiated cardiomyocytes
represent the vast majority. Different explanations for the
lack of proliferative capacity have been proposed: the
presence of the differentiated sarcomeric cytoskeleton may
prohibit cell division and the binucleated and polyploid
phenotype may prevent cell cycle entry. However, cardio-
myocyte mitotic figures have been reported in adult zebrafish
and mice (Jopling et al., 2010; Porrello et al., 2011; Bersell et
al., 2009; Kikuchi et al., 2010), suggesting that the presence of
sarcomeres may not be prohibitive to cardiomyocyte division.
The mechanisms of cell cycle entry and division of adult
cardiomyocytes may involve cellular dedifferentiation. Sarco-
mere disassembly has been reported in proliferating zebrafish
and neonatal mouse and rat cardiomyocytes and correlated
with distinct changes in gene expression (Li et al., 1996;
Dispersyn et al., 2002; Sharov et al., 1997; Kubin et al., 2011).
Oncostatin M, p130, and retinoblastoma protein regulate
dedifferentiation in culture (Kubin et al., 2011; Sdek et al.,
2011). Reversal of epigenetic gene silencing mechanisms may
be involved with cardiomyocyte cell cycle re-entry (Tsang et
al., 2009; Sdek et al., 2011; Ibrahim et al., 2012).
We have demonstrated that neuregulin-induced prolifer-
ation of differentiated adult mouse and rat cardiomyocytes
occurs primarily in the mononucleated portion (Bersell et
al., 2009). Most adult zebrafish cardiomyocytes are mono-
nucleated, which is consistent with their significant prolif-
erative activity during regeneration (Wills et al., 2008).
Newt cardiomyocytes are 98% mononucleated in vivo, but in
culture ~30% acquire a binucleated phenotype by way of
incomplete cytokinesis (Bettencourt-Dias et al., 2003). Of
these bi- and multi-nucleated newt cardiomyocytes, ~20%
re-entered the cell cycle and some divided. It is important to
note that bi- and multi-nucleated cardiomyocytes are
exceedingly rare in newts in vivo (Bettencourt-Dias et al.,
2003). In human infants and children, cardiomyocyte cell
cycle activity occurs predominantly in the mononucleated
fraction (Mollova et al., 2013). A recent report proposeddivision of binucleated cardiomyocytes in mice during the
pre-adolescent growth spurt (Naqvi et al., 2014). In
summary, some evidence suggests that the morphologic
phenotype of cardiomyocytes with respect to mono-/
binucleation may be associated with cell cycle capacity,
although this association may not be strict.
What is the evidence for a distinct phenotype of
differentiated cardiomyocytes that can re-enter the cell
cycle? In animal models where cardiomyocyte cycling has
been induced, cardiomyocytes have been described as
smaller in size (Katz et al., 1992; Mahmoud et al., 2013;
Chakraborty et al., 2013; Liao et al., 2001). In the border
region of ischemic injury, actively cycling cardiomyocytes
have been measured to be smaller in dimensions (Mollova et
al., 2013; Beltrami et al., 2001). In Mollova et al., we
observed cycling human cardiomyocytes in vivo to be
mononucleated (Mollova et al., 2013). In mice, some
mononucleated cardiomyocytes have the ability to undergo
multiple rounds of division in vivo as determined by sequential
labeling schemes and clustering of cardiomyocytes with a
record of cell cycle (Bersell et al., 2009). We found with MIMS
analysis that most cardiomyocytes with evidence for a history
of division were mononucleated and diploid (Senyo et al.,
2013). In summary, independent reports indicate a higher cell
cycle activity inmononucleated as comparedwith binucleated
cardiomyocytes (Senyo et al., 2013). It remains to be
determined whether a proliferation-competent cardiomyo-
cyte phenotype can be defined based on molecular
characteristics.
Cultured cardiomyocytes are a useful tool for mechanistic
studies. In culture, isolated adult cardiomyocytes progres-
sively change their rod-like morphology to a flat shape
coinciding with cytoskeleton reorganization (Malliaras et al.,
2013; Kubin et al., 2011; Claycomb, 1985; Zhang et al.,
2010; Engel et al., 2005). This morphologic change in vitro
may facilitate the ability of mitogenic stimuli to induce cell
division in cardiomyocytes that in vivo may not proliferate
and must be considered when interpreting the results
(Bersell et al., 2009; Kubin et al., 2011; Claycomb, 1985;
Zhang et al., 2010).
Stimulating cardiac regeneration by inducing
cardiomyocyte proliferation
Fetal and 1-day neonatal mice exhibit regenerative capacity
in response to genetically induced disease and surgical
damage, respectively (Porrello et al., 2011; Drenckhahn et
al., 2008). The capacity for scarless repair appears to be
present in mice until the neonatal period (Porrello et al.,
2011; Porrello et al., 2013; Drenckhahn et al., 2008). Within
the first two weeks of life in mice (Soonpaa et al., 1996;
Walsh et al., 2010) and approximately 10–20 years in
humans (Mollova et al., 2013; Bergmann et al., 2009),
cardiomyocytes transition from cell cycle activity to a
non-cycling state. The association between cardiomyocyte
cell cycle activity and regenerative potential has raised
interest in modulating cardiomyocyte proliferation after the
end of the regenerative period.
To regain proliferative capacity in adult cardiomyocytes,
cell cycle checkpoints have been modulated with molecular
interventions. Forced expression of cyclin B1-CDC2, and
538 S.E. Senyo et al.knockdown of p21/p27 have been shown to increase cell
cycle activity of cardiomyocytes in vitro (Bicknell et al.,
2004; Di Stefano et al., 2011). However, cell cycle factors do
not universally activate cell division as over-expression of
cyclin D1 in adult cardiomyocytes promotes DNA synthesis
and multinucleation without proliferation (Soonpaa et al.,
1997). In vivo, cyclin D2, but not cyclin D1 and D3, resulted
in persistent cardiomyocyte DNA synthesis and reduced
scarring after experimental myocardial infarction in mice
(Pasumarthi et al., 2005). Similarly, transgenic expression of
cyclin A2 increased cardiomyocyte cycling and myocardial
regeneration (Chaudhry et al., 2004; Woo et al., 2006).
Overexpression of the adenoviral oncogene E1A induced
cardiomyocyte cycling, followed by apoptosis (Liu and Kitsis,
1996). Overexpression of the transcription factor E2F-1
increased cardiomyocyte apoptosis, whereas overexpression
of E2F4 stimulated cardiomyocyte cycling in vivo (Agah et
al., 1997; Yurkova et al., 2008; Ebelt et al., 2008).
Knock-out of the regulators of the E2F transcription factors,
the pocket proteins Rb and p107, increased cardiomyocyte
cycling (Sdek et al., 2011; MacLellan et al., 2005). Chemical
inhibition and genetic knockout of GSK3β led to increased
cardiomyocyte cycling (Tseng et al., 2006; Kerkela et al.,
2008), which indicates the Wnt signaling pathway as a
potential target for stimulating cardiac regeneration.
Recapitulating developmental signaling pathways in differ-
entiated cardiomyocytes has the potential to stimulate
proliferation. Under this premise, developmental signaling
pathways should be present in differentiated cardiomyocytes
and available for activation. For example, developmentally
expressed cell surface receptors could be stimulated with
extracellular factors. Neuregulin and its receptors on cardio-
myocytes, the receptor tyrosine kinases ErbB2 and ErbB4
regulate developmental cardiomyocyte proliferation and
differentiation (Wadugu and Kuhn, 2012). Administration of
neuregulin and oncostatinM, an extracellular factor activating
cytokine receptors has been shown to stimulate cardiomyo-
cyte proliferation (Bersell et al., 2009; Kubin et al., 2011). In
addition, intracellular components of developmental signaling
pathways can be targeted. For example, modifications of
positive and negative regulators of the Hippo pathway have
been shown to enhance neonatal and adult mouse cardiomyo-
cyte cycling (Heallen et al., 2013; von Gise et al., 2012; Xin
et al., 2011).
Delivery of neuregulin1 (Nrg1), fibroblast growth factor
(FGF1) with pharmacologic p38 MAP kinase blockade, and
periostin peptide has been demonstrated to promote myocar-
dial repair (Bersell et al., 2009; Engel et al., 2006; Kuhn et al.,
2007).We have shown that administration of recombinant NRG1
induces cell cycle and division markers in cardiomyocytes,
resulting in generation of new cardiomyocytes and improved
function (Bersell et al., 2009). We have also demonstrated that
local delivery of a peptide of periostin in rats immediately after
MI increased cardiomyocyte proliferation, reduced scar forma-
tion, and improved myocardial function (Kuhn et al., 2007).
Mice with a germline knockout of the periostin gene showed a
verymild general phenotype andwere viable (Rios et al., 2005).
Other periostin germline knockouts did not reduce cardiomyo-
cyte cycling or myocardial growth, but showed reduced scar
formation and impaired repair after myocardial infarction
(Shimazaki et al., 2008; Lorts et al., 2009). Overexpression of
the full-length periostin gene under control of the α-MHCpromoter in differentiated cardiomyocytes did not increase
cardiomyocyte cell cycle activity (Lorts et al., 2009). In this
context, is important to note that normally, cardiomyocytes do
not express the periostin gene. In addition, there is evidence for
functional significance of a periostin splice variant, but a
definitive structure–function relationship has not yet been
achieved (Litvin et al., 2006). We have subsequently reported
periostin peptide-stimulated cardiomyocyte mitosis in large
animals (Polizzotti et al., 2012). This was recapitulated in an
independent analysis, which also showed a reduction of scar
formation, but increased fibrosis on microscopic analysis
(Ladage et al., 2013). In summary, the apparent discrepancy
between administration of periostin peptide and manipulation
of the full-length gene with respect to cardiomyocyte cell
cycling may be associated with fundamental differences of the
activated mechanisms, possibly due to specifics of the
molecular strategy (truncated peptide vs. full-length gene).
These differences can also be due to timing (acute peptide
therapy vs. chronic overexpression by transgene) and heterol-
ogous expression in cardiomyocytes. This comparison indicates
that specifics of molecular interventions matter and should
ideally be addressed with side-by-side experimentation.Discussion
Multiple studies have demonstrated that adult mammals renew
cardiomyocytes at a very low rate from a cellular source of
pre-existing cardiomyocytes (Senyo et al., 2013; Malliaras et
al., 2013; Ellison et al., 2013; Mollova et al., 2013). Endogenous
progenitor cells may play a role in therapeutic approaches. The
2012 POSEIDON clinical trial shows some potential for autolo-
gous mesenchymal cells in patients with ischemic cardiomyop-
athy (Hare et al., 2012; Traverse et al., 2012). The release of
cell cycle blocks in adult cardiomyocytes and progenitor cell
activation can facilitate an increase in cell cycle activity
(Malliaras et al., 2013; Mollova et al., 2013; Loffredo et al.,
2011; Mahmoud et al., 2013). An emerging line of research
seeks to define endogenous mechanisms of cardiomyocyte
proliferation in the context of post-natal development and in
response to neonatal injury (Garbern and Lee, 2013).
Establishing standards for defining cardiac regeneration
would be useful for comparing different studies and
ultimately for advancing the field. These standards should
be high and broadly accepted. When using metabolic labels
(for example BrdU and labeled thymidine preparations), the
labeling strategy should be clearly described, and the
labeling kinetics should be measured (blood concentrations,
effectiveness of cellular labeling). Assay sensitivities should
be quantified and reported. Cardiomyocyte cell cycle
activity should be measured with multiple, direct, and
independent methods on the same sample. A conclusion
that cardiomyocyte proliferation occurred should be sup-
ported by direct quantitative evidence. Stereology is
considered by many as the gold standard for quantifying
cardiomyocytes in intact hearts (Muhlfeld et al., 2010). Cell
cycle outcomes should be determined, i.e. multinucleation,
ploidy, and division. Cell cycle activity should be examined
and reported separately in diploid-mononucleated and bi-/
multinucleated cardiomyocytes, whenever possible. Given
the plasticity of cardiomyocytes in culture, timelines of in
vitro experiments have to be reported. Karyokinesis and
539Cardiac regeneration based on mechanisms of cardiomyocyte proliferation and differentiationcytokinesis of cultured cardiomyocytes can be documented
by video microscopy.
Regenerative cardiac medicine may be able to harness the
growing understanding of endogenous cardiomyocyte renewal,
stimulated cardiomyocyte proliferation, and progenitor differ-
entiation (Garbern and Lee, 2013; Chong et al., 2014). To
address these processes in the tissue context, heterocellular
interactions have to be addressed. The extracellularmatrixmay
have a potential function. The injury border region represents a
transient space for cellular proliferation. Cardiac stromal cells,
including fibroblasts, are known to communicate directly with
cardiomyocytes via paracrine factors and cell-to-cell junctions,
which may contribute to cell cycle signaling in cardiomyocytes
(Ieda et al., 2009).Acknowledgments
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